| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| KIG MANAGEMENT | 14,826 | 7,413 | 7,413 |
| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| UNRELATED BUSINESS INCOME SHORT-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 109 | COST | 0 | 109 | |||||
| UNRELATED BUSINESS INCOME LONG-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 2,326 | COST | 0 | 2,326 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | CONTRIBUTIONS TOTALING $757,000 WERE MADE BETWEEN JULY 1, 2021 AND JUNE 30, 2022 TO A DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731; WITH $947,500 BEING DISTRIBUTED IN THE SAME FISCAL YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID (STATEMENT #16). THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE HUGH AND CHARLOTTE MACLELLAN CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| NXPHASE | 8,110 | 8,110 |
| UBS 5653 | 186,225 | 144,465 |
| UBS 5654 | 293,842 | 235,125 |
| UBS 5656 | 1,008,473 | 787,917 |
| UBS 5657 | 165,398 | 125,465 |
| UBS 5658 | 2,242,636 | 2,219,490 |
| UBS 5659 | 394,993 | 360,580 |
| UBS 5817 | 1,216,089 | 907,972 |
| UBS C0045 | 455,311 | 413,640 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AD FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 50,516 | 50,516 |
| AERIAL BIOPHARMA, LLC | AT COST | 1,487,172 | 0 |
| ARRIVO BIOVENTURES, LLC | AT COST | 455,230 | 500,000 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 267,047 | 390,977 |
| BI FUND I, A SERIES OF PATHBREAKER SPV, LP2 | AT COST | 50,432 | 50,432 |
| C-III RECOVERY FUND II LP | AT COST | 172,067 | 313,210 |
| CEVIAN CAPITAL II, LP | AT COST | 306,884 | 535,837 |
| DE FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 38,159 | 38,160 |
| DYNAMO OPPORTUNITY FUND I, LP | AT COST | 136,900 | 136,900 |
| DYNAMO FUND I, LP | AT COST | 378,601 | 2,548,046 |
| DYNAMO FUND II, LP | AT COST | 299,019 | 367,242 |
| DYNAMO-GATIK LLC | AT COST | 45,409 | 45,463 |
| DYNAMO-SKUPOS, LLC2 | AT COST | 59,660 | 60,000 |
| DYNAMO-STORD SPV II, LLC | AT COST | 100,846 | 409,154 |
| DYNAMO SVT ROBOTICS SPV II, LLC | AT COST | 12,862 | 12,584 |
| DYNAMO-VECTOR, LLC | AT COST | 37,926 | 38,015 |
| ESO VENTURE FUND V, LP | AT COST | 75,000 | 75,000 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 320,755 | 615,152 |
| GCM GROSVENOR MACLELLAN INVESTMENT FUND LP | AT COST | 22,417 | 21,848 |
| GOODWATER CAPITAL IV L.P. | AT COST | 193,272 | 205,364 |
| GOODWATER INFINITY II, LP | AT COST | 283,297 | 256,894 |
| H20EY | AT COST | 208,418 | 212,529 |
| H2OEY VENTURES II, LLC | AT COST | 184,555 | 185,455 |
| KERN CAPITAL LLC | AT COST | 100,000 | 250,000 |
| KERN MEDICAL IV, LLC | AT COST | 0 | 40,000 |
| KERN GENOMIC LLC | AT COST | 40,000 | 19,200 |
| KERN ODYSSEUS LLC | AT COST | 100,000 | 100,000 |
| KNOPP BIOSCIENCES LLC | AT COST | 353,090 | 2,235,000 |
| IR B FUND, A SERIES OF PATHBREAKER SPV, LP | AT COST | 100,185 | 100,186 |
| IR C, A SERIES OF PATHBREAKER SPV, LP | AT COST | 50,057 | 50,058 |
| LAVACA CAPITAL CONVEXITY FUND LP | AT COST | 500,000 | 477,722 |
| MIDNIGHT PHARMA, LLC | AT COST | 14,757 | 55,590 |
| NEXGEN VENTURES FUND II, LP | AT COST | 194,170 | 288,550 |
| NORTH AVENUE CAPITAL, LLC | AT COST | 0 | 69,874 |
| ON FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 100,638 | 253,380 |
| ON FUND II, A SERIES OF PATHBREAKER SPV, LP | AT COST | 50,269 | 50,269 |
| OR FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 75,508 | 75,509 |
| PATHBREAKER FRAMEWORK SPV SERIES A | AT COST | 116,742 | 116,742 |
| PATHBREAKER VENTURES FUND II LP | AT COST | 298,421 | 397,830 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 603,869 | 1,040,657 |
| RA CAPITAL HEALTHCARE FUND, LP | AT COST | 378,496 | 273,737 |
| RELEVANCE CAPITAL III LP | AT COST | 446,006 | 1,257,006 |
| RESOLUTE CAPITAL PARTNERS FUND IV, L.P. | AT COST | 833,358 | 1,245,768 |
| RESOURCE LAND FUND, III, LLC | AT COST | 36,181 | 34,479 |
| RIVER VI, L.P. | AT COST | 0 | 12,346 |
| RIVER VII | AT COST | 227,414 | 920,552 |
| RU FUND III, A SERIES OF PATHBREAKDER SPV, LP | AT COST | 75,111 | 75,111 |
| SATURN FIVE FRONTIER I LLC | AT COST | 249,984 | 250,000 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 358,208 | 533,209 |
| SI FUND III, A SERIES OF PATHBREAKER SPV, LP | AT COST | 153,046 | 164,372 |
| TO FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 100,970 | 100,970 |
| VALOR OPPORTUNITY FUND I LP | AT COST | 368,222 | 599,086 |
| VALOR OPPORTUNITY FUND II, LP | AT COST | 195,000 | 199,732 |
| VALOR VENTURE FUND II LP | AT COST | 784,450 | 4,760,987 |
| VALOR VENTURE FUND III LP | AT COST | 515,724 | 940,380 |
| VALOR VENTURE FUND IV, L.P. | AT COST | 216,000 | 217,302 |
| GOLUB CAPITAL PARTNERS INTERNATIONAL II, LP | AT COST | 1,159,793 | 1,749,207 |
| HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS FUND | AT COST | 380,714 | 4,181 |
| RITCHIE ENERGY, LLC | AT COST | 0 | 23,299 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| INVESTMENTS RECEIVABLE | 6,304 | 0 | 0 |
| RECEIVABLE - TAX WITHHELD FULCRUM | 0 | 16,636 | 16,636 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| MANAGEMENT FEES THROUGH BROKERS | 69,088 | 69,088 | 0 | |
| PORTFOLIO DEDUCTIONS THROUGH PARTNERSHIPS | 11,776 | 11,776 | 0 | |
| INVESTMENT INTEREST THROUGH PARTNERSHIPS | 144,646 | 144,646 | 0 | |
| OTHER PARTNERSHIP DEDUCTIONS | 245,096 | 245,096 | 0 | |
| NON DEDUCTIBLE EXPENSES THROUGH PARTNERSHIPS | 22,784 | 0 | 0 | |
| OTHER PARTNERSHIP MANAGEMENT FEES | 5,233 | 5,233 | 0 | |
| OFFICE EXPENSE REIMBURSEMENTS | 18,500 | 0 | 18,500 | |
| BANK CHARGE & WIRE FEE | 1,518 | 1,138 | 380 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| PARTNERSHIPS ROYALTIES | 5 | 5 | 5 |
| OTHER MISC INCOME | 5,003 | 5,003 | 5,003 |
| PARTNERSHIPS OTHER PORTFOLIO INC | 89,849 | 89,849 | 89,849 |
| PARTNERSHIPS OTHER INCOME | 10,897 | 10,897 | 10,897 |
| UNRELATED BUSINESS INCOME | -28,512 | 0 | -28,512 |
| PARTNERSHIPS ORDINARY INCOME | -36,112 | -36,112 | -36,112 |
| Description | Beginning of Year - Book Value | End of Year - Book Value |
|---|---|---|
| EARLY DISTRIBUTIONS | 240,380 | 313,354 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX WITHHELD FROM INCOME | 3,625 | 3,625 | 0 | |
| FOREIGN TAX WITHHELD THROUGH PARTNERSHIPS | 4,565 | 4,565 | 0 | |
| FEDERAL AND STATE EXCISE TAX | 53,053 | 0 | 0 |